Rallybio 2026: Revenue $0 Net income ($2.73M), EPS ($0.48) — 10-Q Summary

What happened

Rallybio reported no revenue and a net loss of $2.73 million in 2026, down from $212,000 of revenue and $16.02 million of net income a year earlier. Diluted loss per share was $0.48 versus earnings per share of $2.84.

Confirmed

Global impact / market context

The swing to a loss means Rallybio earned nothing from sales while still spending on research. It agreed to merge with Avenzo, and Avenzo investors will provide $215 million just before the merger to fund the combined company's planned operations.

Confirmed

Rallybio has no product revenue and its drug programs are still in testing, so cash from the Avenzo deal is what keeps operations running. The planned sale of legacy assets and possible contingent value rights, which pay out only if set goals are met, may add cash.

Analyst inference

What to watch

1. The Avenzo merger is expected to close before the end of 2026, subject to closing conditions, and Avenzo investors will provide $215 million immediately before the merger. Confirmed
2. How much cash the sale of legacy assets and any contingent value rights actually bring in will shape the combined company's ability to fund research without raising more money. Analyst inference
3. Near-term research and development will focus on completing ongoing work and preparing programs for a potential transaction or sale, while RLYB332 remains preclinical. Confirmed

Evidence

• Original source link unavailable